Dhriti Gupta’s Post

View profile for Dhriti Gupta, graphic

Sr News Analyst and Writer at Navlin Daily

Breakthrough in #prostatecancer The introduction of #zydus ' unique oral once-daily treatment for advanced prostate cancer in India makes me very happy. Rexigo (relugolix) was introduced by #zydus at a monthly cost of Rs 6,995 (USD 84.22), which is 50% less expensive than injectable options. It provides quick suppression of testosterone and a superior safety profile for adverse events connected to the heart. Relugolix, a relatively inexpensive medication from #zydus, will be made available to treat a growing number of instances; by 2025, it is anticipated that over 47,000 cases will be treated. The availability in India can considerably enhance patients' quality of life. The drug is expected to be a game-changer as it is affordable, has rapid action, and is safe. For a complete read, https://lnkd.in/gpNU7vfm What's your take on this? 🎤

NAVLIN DAILY

NAVLIN DAILY

navlindaily.com

To view or add a comment, sign in

Explore topics